Related references
Note: Only part of the references are listed.IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in US Medicare Patients, 2014-2017
Ping Du et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2021)
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication
Eiichi Ogawa et al.
CLINICAL INFECTIOUS DISEASES (2020)
Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West
Hansen Dang et al.
HEPATOLOGY (2020)
Screening for Hepatitis C Virus Infection in Adolescents and Adults US Preventive Services Task Force Recommendation Statement
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort
Elizabeth C. Verna et al.
JOURNAL OF HEPATOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review
Amit G. Singal et al.
GASTROENTEROLOGY (2019)
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study
Donna M. Evon et al.
JOURNAL OF HEPATOLOGY (2019)
Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma
Nicole E. Rich et al.
Clinical Gastroenterology and Hepatology (2019)
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma
Amit G. Singal et al.
GASTROENTEROLOGY (2019)
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
Amit G. Singal et al.
GASTROENTEROLOGY (2019)
710PPractice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada
J-L Raoul et al.
ANNALS OF ONCOLOGY (2018)
Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma
Lauren A. Beste et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma
Giuseppe Cabibbo et al.
JOURNAL OF HEPATOLOGY (2017)
Superiority of Interferon-Free Regimens for Chronic Hepatitis C The Effect on Health-Related Quality of Life and Work Productivity
Zobair M. Younossi et al.
MEDICINE (2017)
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection A Systematic Review
Oluwaseun Falade-Nwulia et al.
ANNALS OF INTERNAL MEDICINE (2017)
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
Z. M. Younossi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1,-2, and-3 clinical trials
Zobair M. Younossi et al.
HEPATOLOGY (2015)
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus
Amit G. Singal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies
Erik von Elm et al.
ANNALS OF INTERNAL MEDICINE (2007)
Share Paper
